6/29/2010

Sun Pharmaceutical Industries will discontinue selling its copy of injectable cancer drug Eloxatin in the U.S. beginning next month. The move is in compliance with a court order related to a patent lawsuit from Eloxatin maker Sanofi-Aventis.

Full Story:
Reuters

Related Summaries